Intellia Therapeutics, Inc. (NTLA) shares rallied 7.6% in the last trading session to close at $12.6. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 4.1% loss over the past four weeks.
Intellia Therapeutics’ share price gain appears to reflect growing investor confidence in its regulatory progress and financial position. The FDA accepted the biologics license application for lonvoguran ziclumeran (lonvo-z), Intellia’s investigational CRISPR-based treatment for hereditary angioedema (HAE), under Priority Review, with a March 10, 2027 decision date. Moreover, the company has secured an OrbiMed debt facility of up to $400 million in September, including $75 million upfront, helping support development and potential commercialization.
This company is expected to post quarterly loss of $0.82 per share in its upcoming report, which represents a year-over-year change of +10.9%. Revenues are expected to be $10 million, down 27.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Intellia Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NTLA going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Intellia Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Adma Biologics (ADMA), another stock in the same industry, closed the last trading session 1.9% higher at $10.33. ADMA has returned 7.3% in the past month.
For Adma Biologics, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.19. This represents a change of +18.8% from what the company reported a year ago. Adma Biologics currently has a Zacks Rank of #3 (Hold).
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intellia Therapeutics, Inc. (NTLA): Free Stock Analysis Report
ADMA Biologics Inc (ADMA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).